Coherus BioSciences Secures $75 Million Credit Financing with HealthCare Royalty Partners
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners. “We are pleased to have the renewed support of HealthCare Royalty Partners,” said Denny Lanfear, President and CEO of Coherus. “This financing bolsters our cash position and working capital, enabling us to accelerate and enhance the manufacture and sale of UDENYCA™ (pegfilgrastim-cbqv), which we launched January 3, 2019. We look forward to providing significant value to cancer patients, oncology clinics and hospitals, as well as providing significant savings to payers.” “This investment reflects our continued confidence in the Coherus leadership team, as well as their ability to execute on their commercial plan,” said Clarke Futch, Managing Partner and Chairman of the Investment Committee of Healthcare Royalty Partners. “We
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Drug Delivery Technologies market is projected to grow at a CAGR of 5.5% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years [Yahoo! Finance]Yahoo! Finance
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 3/13/24 - Miss
CHRS
Analyst Actions
- 3/18/24 - HC Wainwright
CHRS
Sec Filings
- 4/15/24 - Form ARS
- 4/15/24 - Form DEFA14A
- 4/15/24 - Form DEF
- CHRS's page on the SEC website